Articles tagged with Cancer Immunotherapy
Researchers describe results using cladribine-based combination epigenetic and immunotherapy in MCL, achieving an increased overall survival greater than 40 months with durable remissions without relapse for longer than 5 years. The approach is promising in the treatment of MCL and potentially other previously treatment-refractory canc...
Researchers have demonstrated successful re-treatment with CAR T cell therapy for patients whose cancers relapsed after previous treatment. The novel fourth-generation CAR T therapy, huCART19-IL18, showed safe and potent antitumor efficacy in a Phase I clinical trial.
Researchers have identified three new subtypes of glioblastoma, a type of brain cancer, based on the presence of specific non-cancer cells. These subtypes may help identify targeted therapies, such as immunotherapies, for improved patient outcomes.
A Mount Sinai study found that certain inflammatory markers can predict which patients are more likely to respond to COVID-19 immunotherapies. The researchers identified a subtype of COVID-19 patients with hyperinflammation who could benefit from pacritinib, an anti-cancer drug.
Researchers review myeloid-derived suppressor cells' phenotypes, mechanisms of immunosuppression, and roles in cancer treatment. Studies on non-malignant diseases, such as autoimmune disorders and obesity, are lacking, highlighting the need for further investigation.
Researchers at University of Chicago Medical Center have identified biomarker predicting response to combined RT and ICB treatment in mNSCLC. High tumor aneuploidy associated with improved survival when RT is added to ICB, while low aneuploidy shows no survival benefit.
Researchers at CU Anschutz Medical Campus have identified a less invasive way to treat HPV-unrelated head and neck squamous cell carcinomas by combining radiation with immunotherapy. The approach resulted in remarkable success rates, including 75% of patients experiencing major pathological responses or complete responses.
Researchers at University of Pittsburgh have designed novel nanoparticles that co-deliver a chemotherapy drug and a novel immunotherapy, shrinking tumors in mouse models of colon and pancreatic cancer. The therapy silences a gene involved in immunosuppression by blocking Xkr8 protein distribution on the cell membrane.
A single drug compound attacks prostate cancer on several fronts by triggering immune cells to attack, helping them penetrate the tumor, and cutting off its ability to use testosterone as fuel. The study found that the drug activates anti-cancer T cells in a novel way and increases their ability to penetrate tumors.
A new study reveals that the protein fragile X mental retardation protein (FMRP) plays a crucial role in helping tumors evade immune destruction, leading to treatment resistance. FMRP regulates a network of genes and cells in the tumor microenvironment, contributing to its ability to hide from immune cells.
The ESMO Asia Congress 2022 will focus on the latest scientific and clinical advances in oncology, with a special emphasis on the Asia-Pacific region. Media representatives can register for coverage through the official media registration form.
A comprehensive genomic analysis of over 200 patients with metastatic urothelial carcinomas identified potential treatment options for nearly 70% of patients. The study found that integrating clinical and molecular features could predict response to immunotherapies, offering hope for personalized treatment approaches.
Researchers from Vanderbilt University Medical Center have identified the cardiac antigen α-myosin as the mechanism for immunotherapy-related myocarditis, a rare but deadly complication affecting less than 1% of patients. The discovery sets the framework to identify biomarkers and develop strategies to tolerate immunotherapy in at-risk...
Researchers developed an algorithm using amino acid sequences of proteins called T cell receptors to predict patient response to treatment, providing insights into the biology behind an effective response. The algorithm, DeepTCR, identified patterns that are predictive of patient response as accurately as known biomarkers.
A five-year review of focused ultrasound treatment for essential tremor found that patients experienced significant reductions in tremor symptoms, with benefits lasting long-term and no reported progressive or delayed complications. The study represents the largest long-term assessment yet conducted on the procedure.
A new nanotechnology platform has successfully converted solid tumor cells into immune-activating targets, making them more receptive to immunotherapy. The approach uses a bispecific nanoconjugate to attach an immune-activating molecule to the surface of cancer cells, triggering an immune response.
Researchers developed a new taxonomy of bowel cancer using gene interaction networks, grouping tumors into six distinct clinical and molecular subtypes. This classification system could aid in precision medicine by tailoring treatments to individual patients.
Researchers used DNA barcoding to track breast cancer cells over time, finding that some cells can suppress killer T-cells and reduce MHC1 expression to evade the immune system. This study suggests epigenetic mechanisms may play a role in cancer cell adaptation and provides potential targets for therapies.
A new study led by University of Cincinnati researcher Trisha Wise-Draper found that immunotherapy treatments may worsen COVID-19 disease in patients with baseline immunosuppression. However, patients who received COVID-19 vaccinations had less severe COVID-19 outcomes.
Researchers at Boston University have developed a novel platform that improves the production of T cells and Natural Killer cells from human induced Pluripotent Stem Cells (iPSCs) using Notch stimulation. This breakthrough has potential clinical applications in oncology, autoimmune diseases, and immunodeficiencies.
Researchers discover exceptional individual with 12 tumors, shedding light on early detection methods and immune system response. Single-cell analysis technology shows promise in identifying cells with tumor potential before symptoms appear.
A study reveals that interleukin 34 (IL-34) modulates the balance between two myeloid-derived suppressor cell populations, leading to immunosuppression and chemoresistance in triple-negative breast cancer. Neutralizing IL-34 with a drug reduces tumor growth and susceptibility to chemotherapy.
A comparison of two cancer drugs reveals that life cycle management strategy is crucial for a drug's commercial success. The research found that product sales are closely linked to the number of approved indications and inter-organizational alliances.
Researchers at Cleveland Clinic are exploring the role of inflammatory cytokines in cancer treatment, with a focus on developing personalized therapies. The five-year grant will help identify potential windows for therapy and optimize treatment strategies for individual cancers.
Advanced nanoparticles carrying a bacterially derived compound target the STING pathway, disrupting blood vessels and stimulating an immune response. This approach suppresses tumor growth and metastasis in several types of cancers.
A new study reveals that urolithin A from pomegranates can rejuvenate T cells by recycling and renewing mitochondria, enhancing their ability to fight tumors. The researchers plan to investigate the application of urolithin A in clinical trials for colorectal cancer.
A Phase II study found that the combination of relatlimab and nivolumab was safe and completely cleared all viable tumor in 57% of patients with stage III melanoma before surgery. The overall pathologic response rate was 70%, with no grade 3 or 4 immune-related adverse events reported.
A phase II clinical trial has demonstrated the effectiveness of nivolumab, an immune checkpoint inhibitor, in treating advanced cutaneous squamous cell carcinoma. The study found a significant response rate of 58.3% among patients who received nivolumab, supporting its use as a standard therapy for this disease.
A new approach combines an immunotherapy agent with a molecular delivery system that targets tumor acidity, successfully eradicating colorectal tumors in mice. The researchers believe this method may increase the effectiveness of STING agonist therapy for cancer patients.
Researchers identified urolithin A as a compound that improves function of immune cells against cancer. The study found that urolithin A induces mitophagy in T cells, recycling and renewing mitochondria to enhance tumor-fighting capabilities.
Researchers analyzed 408 patients receiving immune checkpoint inhibitor therapy and found no increased risk of side effects from receiving both immunotherapy and the vaccine. The study supports NCCN's recommendations for COVID-19 vaccination in people with cancer, citing strong protection against severe COVID-19 for all variants.
A Mediterranean diet rich in fibre, mono-unsaturated fatty acids and polyphenols has been associated with improved immunotherapy response rates and progression-free survival in advanced melanoma patients. The diet was also found to reduce the likelihood of drug-induced immune-related side effects.
The event will cover various topics including microbiota dysbiosis, oral and vaginal microbiota, and their impact on diseases like depression, cancer, and respiratory infections. The meeting aims to accelerate Microbiota medicine applications through strategic discussions.
A recent study found that cancer biomarker data is biased towards European populations, potentially misclassifying patients of Asian or African descent. The researchers propose a computational approach to correct this bias, which could have significant implications for treatment selection.
A recent clinical trial found that patients with advanced melanoma who received immunotherapy first had a 20% higher two-year overall survival rate compared to those who initially got targeted therapies. The study also showed improved progression-free survival rates for those on immunotherapy.
The NCCN Annual Congress on Hematologic Malignancies will address key findings on chronic lymphocytic leukemia management and CAR T-cells in diffuse large B-cell lymphoma. The event also features updates on immunotherapies in multiple myeloma treatment.
Researchers at UMC Utrecht will investigate how intestinal microbiota impacts cancer immunotherapy and therapy side effects. The project aims to develop microbiota-targeted therapies to improve ICI treatment effectiveness and reduce severe inflammation.
Research by Saarland University scientists reveals that killer T cells become more effective and powerful with age, making them a promising tool for cancer immunotherapy. The study's findings suggest that older patients' immune systems can produce more potent killer cells to fight off pathogens.
Research reveals that tumor cells form temporary structures to avoid destruction by the immune system. The findings suggest that timed inhibition of relevant signaling pathways is necessary alongside immunotherapy to prevent tumor resistance.
A new study found that a single research test can predict which patients are likely to experience severe side effects or have their cancer recur after treatment with immunotherapies. The test uses autoantibody signatures to identify patients at risk of immune-related adverse effects.
A new study led by Ohio State University researchers found that atezolizumab is a safe and effective treatment option for stage IB-IIIB non-small cell lung cancer patients prior to surgery, with survival rates reaching 80% at three years post-treatment. The study also identified new blood markers that can help predict treatment response.
A new study provides valuable insights into the roles of B cells and plasma cells in early-stage lung cancer biology, highlighting their influence on tumor development and treatment outcomes. The research also reveals environmental factors and molecular features that contribute to the landscape of infiltrating immune cells.
Bladder cancer researchers discovered a subset of CD8 T cells that adapts to tumor evasion strategies, offering a strategy to reduce tumor cells' ability to fight them off. The study also identified potential ways to make immunotherapy more effective against this deadly cancer by targeting the HLA-E/NKG2A axis.
In an international clinical trial, 63.3% of patients with stage II-IV cutaneous squamous cell carcinoma saw their tumors nearly or completely disappear when treated with immunotherapy before surgery. The anti-PD1 therapy cemiplimab was well-tolerated and met its primary endpoint with a pathologic complete response rate of 50.6%.
Researchers found that starting pembrolizumab before surgery significantly improves the outlook for patients with stage III-IV melanoma. The study showed a 42% lower event rate in patients receiving neoadjuvant therapy compared to those receiving adjuvant therapy.
A phase 3 study shows that tumour-infiltrating lymphocytes (TIL) therapy significantly improves progression-free survival compared to standard immunotherapy in patients with advanced melanoma. The treatment reduces disease progression or death by 50% in patients treated with TILs.
Researchers have developed a new safety system for CAR-T cells, called VIPER CAR-T cells, that can be turned on or off. This allows doctors to target cancer more aggressively while minimizing side effects. The new system uses an FDA-approved antiviral drug to control the cell's activity.
A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients. The three-drug combination showed a 27% lower risk of progression or death compared to the two-drug control, with a median progression-free survival of 11.3 months.
Researchers conducted a study on administering immunotherapy drug pembrolizumab before surgery for oral cavity cancer and found no increased rates of complications during and after surgery. The findings are encouraging for patients who have not previously received treatment for their oral cavity cancer, suggesting that complication rat...
A phase II study found that treating late-stage, treatment-resistant melanoma patients with a combination of Azacitidine and Carboplatin significantly increases their survival times. The treatment re-sensitized cancer cells to immunotherapy, allowing the body's immune system to fight the cancer.
A combination of immunotherapy and virotherapy using myxoma virus provides new hope for patients with treatment resistant cancers. The approach boosts the immune capacity to effectively target and destroy cancer cells, inducing a form of cell death called autosis.
A UTHSC-led team has received a $3.16 million National Cancer Institute grant to develop a cancer immunotherapy drug that boosts the immune system response to destroy tumor cells.
Researchers at Texas Biomed have developed a modified tuberculosis vaccine that can treat non-muscle invasive bladder cancer without strong side effects. The delipidated vaccine triggers well-regulated immune responses and reduces inflammation, making it more effective than traditional treatments.
Researchers developed a small molecule that effectively controls tumor growth by inhibiting PD-1/PD-L1 binding, overcoming accessibility and cost issues of existing antibody treatments. The new molecule has advantages in terms of affordability and oral administration, making immunotherapy more accessible to all cancer patients.
Researchers at the University of Pittsburgh have discovered that even terminally exhausted T cells retain some capacity to function again. They identified approaches to overcome exhaustion by targeting co-stimulation pathways and reprogramming T cells to be resistant to hypoxia, a common tumor microenvironmental signal.
Researchers developed a method to produce generic CAR T cells from induced pluripotent stem cells (iPS cells), which could be produced at scale for multiple patients. The new cells showed enhanced anti-tumor activity and comparable efficacy to current clinical-grade cells.
Researchers at Cedars-Sinai Cancer identified genetic signatures linked to patient response to immunotherapy in bladder and other cancers. High DDR1 expression is associated with 'cold' tumors, while high DDR2 is linked to 'hot' tumors.
The University of Cincinnati is conducting a study on a potential new treatment for pancreatic cancer using SapC-DOPG, a nanotechnology drug delivery system. The treatment has shown promise in reducing tumor growth by 50-80% in animal models and aims to develop an effective immunotherapy treatment.
Researchers discovered that liver cancer cells modify their metabolism to leave them susceptible to disruptions in arginine supply, a key molecule. A three-pronged approach targeting tumor metabolism, blocking survival-promoting responses, and starving tumors of arginine can induce senescence, making cancer cells killable.
Researchers investigated the effects of neoadjuvant chemoradiotherapy on CD8+ tumor-infiltrating lymphocytes, PD-L1, and mucin expression in rectal cancer patients. The study found that nCRT exposure was associated with higher mucin expression and a non-significant difference in PD-L1 expression, suggesting an immunosuppressive phenotype.